Regeneron Pharmaceuticals Inc (REGN)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	3,953,600	3,991,100	4,299,000	4,182,700	4,338,400	5,370,300	5,686,800	7,933,600	8,075,300	6,995,500	6,205,400	4,003,800	3,513,200	3,156,000	2,983,500	2,279,300	2,115,800	2,144,200	2,069,300	2,427,600
Total stockholders’ equity	US$ in thousands	25,973,100	24,904,400	24,017,900	23,495,200	22,664,000	21,438,800	20,687,800	19,914,700	18,768,800	17,258,000	15,127,300	11,977,000	11,025,300	10,125,500	9,057,400	12,133,000	11,089,700	10,504,400	9,755,900	9,444,700
ROE		15.22%	16.03%	17.90%	17.80%	19.14%	25.05%	27.49%	39.84%	43.03%	40.53%	41.02%	33.43%	31.86%	31.17%	32.94%	18.79%	19.08%	20.41%	21.21%	25.70%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $3,953,600K ÷ $25,973,100K
= 15.22%

Regeneron Pharmaceuticals, Inc.'s return on equity (ROE) showed a decreasing trend over the past eight quarters, with the ROE declining from 39.84% in Q1 2022 to 15.22% in Q4 2023. This suggests that the company's profitability in generating returns from shareholders' equity has been gradually decreasing over this period. The significant drop in ROE from Q2 2022 (27.49%) to Q3 2022 (25.05%) may warrant further investigation into the factors contributing to this decline.

A declining ROE could indicate decreasing efficiency in utilizing equity to generate profits or declining profitability relative to equity investments. Investors and analysts may want to assess the company's financial strategy, operational performance, and capital structure to understand the reasons behind this trend and evaluate the sustainability of Regeneron Pharmaceuticals, Inc.'s financial performance.